WO1987003690A1 - Particle-bound binding component immunoassay - Google Patents

Particle-bound binding component immunoassay

Info

Publication number
WO1987003690A1
WO1987003690A1 PCT/US1986/002637 US8602637W WO1987003690A1 WO 1987003690 A1 WO1987003690 A1 WO 1987003690A1 US 8602637 W US8602637 W US 8602637W WO 1987003690 A1 WO1987003690 A1 WO 1987003690A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
binding
filter
component
particles
material
Prior art date
Application number
PCT/US1986/002637
Other languages
French (fr)
Inventor
David Lee Marshall
Original Assignee
Murex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56927Chlamydia

Abstract

An immunoassay method for the detection or quantitation of an analyte suspected of being in a solution comprising: (a) combining said specimen, a first binding component, insoluble particles, and second binding component labelled with a signal generating material in a solid phase retention and separation apparatus having a sufficient pore size such that said particles are trapped within said filter yet permitting rapid passage of fluid therethrough in such a manner that an immunological reaction occurs if analyte is present in said specimen, resulting in the formation of an immunocomplex of insolubilized first binding component: analyte: second labelled binding component on or within said filter means; (b) separating bound from unbound material; and (c) determining the presence and/or amount of signal produced which is correlative with the amount of analyte present in the solution.

Description

PARTICLE-BOUND BINDING COMPONENT INHUNOASSAY

BACKGROUND OF THE INVENTION FIELD OF THE INVENTION

The field of this invention relates to a solid phase system for performing an immunoassay for detection and quantitation of an analyte suspected of being in a specimen. More particularly, the invention relates to a method using a solid support surface consisting of particles to which can be bound a binding component or antigen-

PRIOR ART •

Numerous methods have been developed utilizing immunoassay techniques for more precise and reliable ways to quantitate an amount of analyte in a specimen. The rapid, quantitative and cost-efficient results desired by the medical and diagnostic testing industry have provided the impetus for novel means of accomplishing these goals. There are two types of assay systems currently used. One is a homogeneous system whereby the assay is performed in a single phase. Antibody and analyte are allowed to react together and a labelled material is introduced which binds to the antibody or antigen after an antibody:antigen complex Fias formed. The label generates a signal which is readable when present in the reaction zone or solution. The signal is correlative with the amount of analyte present in solution. This indirect measurement is generally used because of the difficulty of direct measurement of many analytes. The second type of system is a heterogeneous assay which is a two-phase system where there is a solid, or bound, phase and a liquid, or an unbound phase, requiring an additional step so as to separate the bound from unbound material. Typically, a solid support surface is used as the bound phase, to which is attached an antibody or antigen via a chemical bond or adsorption. Various types of solid support surfaces have been developed to improve the efficiency of the immunological reaction between antibody and antigen, and, to increase the efficiency of the separation step. An inefficient or incomplete separation of bound from unbound can result in unbound label remaining in the reaction zone after the separation step, which will cause a positive signal to be read where there -is no antigen present. An efficient binding and subsequent separation are two of the most important aspects of a desirable assay.

Particles have been used in agglutination assay procedures for some time in order to overcome the drawbacks of inefficient binding. In this type of system soluble antigens will combine with their specific antibody to form a precipitate, in which the antigen-antibody complexes form large aggregates which are insoluble. The same antigens, if attached to particulate matter such as latex particles or bacterial cells, will form agglutinates or clumps. The agglutination reaction can be detected and quantified using visual or instrumentation means such as light-scattering or absorption techniques (Bellanti, "Immunology II", W.B. Saunders Company, Philadelphia, 1978, p. 212). Though the test is commonly used in the clinical laboratory, it suffers from several limitations, such as serum interferences, insensitivity, and, most importantly, from the perspective of the technician or scientist performing the test, the subjective judgment of the assay endpoint. While the method is convenient for qualitative analysis, it is inadequate for quantitative analysis, especially of very low concentrations of analytes. Latex particles have been used as labels for the analyte of interest, whereby the assay reTies on the use of an agglutination reaction to decrease the number of particles of a particular size present in the assay mixture (Boguslaski, et al., "Clinical Immunochemistry," Little, Brown and Company, Boston, 1984, p.211).

Various material have been used as support surfaces, including glass rods, glass beads, silica impregnated strips, glass fiber, filter paper, cellulose or its derivatives, Sepharose beads, plane polymeric surfaces, magnetizable solid phase cellulose/iron oxide particles, ferratin, and the like.

Coated test tubes and trays have the limitation that only the inner surface of the vessel is coated with the solid phase. Material in the center of the solution will not be in intimate contact with the solid phase until and unless agitated; and even then only over a comparatively long period of time. The lack of surface area prevents the rapid establishment of an equilibrium between the bound and unbound phase.

Physical separation of the bound phase from the unbound phase is required in heterogeneous assays. Most often the bound phase is retained for measurement; however, the unbound label can also be quantified. Separation is generally accomplished by one of several methods including chromatography, filtration, electrophoresis, adsorption, precipitation, or centnfugation. It is preferable to use a method which is adaptable for use in automated equipment or in a system that can be used by a trained technician.

Thus, Michael E. Jolly, Ph.D., discloses in Pandex Laboratories Research Report No. 1, July 1983, a particle concentration fluorescence immunoassay wherein 0.6-0.8um polystyrene particles are bound to the antigen of interest. A first antibody directed against the antigen and a labelled second antibody directed against the first antibody are contacted with the bound antigen. The label is limited to a fluorescent molecule and is read after separation by front-surface fluorimetry.

Such procedure contains deficiencies in that it is limited to fluorescent signal and detection means and it is also -limited to front-surface reading; which does not appear to be pragmatic for rear* surface viewing. Moreover, the particles disclosed are only composed of polystyrene and 0.6-0.8um in size, rather than a broad range of useful particle compositions and sizes. Additionally, no filter separation of particles is performed.

U.S. Patent No. 4,201,763, issued to Monthony, et al . , discloses water insoluble hydrophilic polymeric particles in the performance of a sandwich or competitive immunoassay. The method is limited to the use of a fluorescent label and therefore lacks the versatility of uses in situations where nonfluorescent labels are preferable.

U.S. Patent No. 4,415,700, issued to Batz, et al., describes hydrophilic latex particles consisting of a homo- or co-polymer of monomers containing at least one epoxy group and at least one polymeπ'zable carbon-carbon double bond in the molecule. The method using the particles is a competitive assay wherein labelled first antibody bound analyte and unlabelled first antibody bound analyte compete for binding sites on a particle bound second (anti-first antibody) antibody. Again, the invention is limited to one type of label, in this instance an enzyme, and is also limited to a particular particle composition.

With the emergence of the physician's office and self- testing markets, there is a need for a separation technique that can be used by relatively unskilled users. A solid phase that would be compatible with an easy-to-use filter separation system, that provided accurate and repeatable results would be advantageous. Such a method should have a solid phase that permits a rapid equilibrium to be established between* the antibody and antigen so as to promote rapid binding of the two; it should also be convenient and inexpensive; and, it should be usable in settings in addition to a hospital or laboratory, i.e., the physician's office or in the home.

SUMMARY OF THE INVENTION

The present invention relates to a method for performing a heterogeneous immunoassay for the detection and quantisation of an analyte suspected of being in a specimen which overcomes the problems heretofore encountered.

More particularly, the present invention is directed to a method comprising a relation between finely divided particulate solid material capable of forming a stable suspension in a liquid medium and an inert porous filter matrix means of sufficient pore size to retain the particles on or within the filter matrix, yet permitting the flow of liquid therethrough. Material thus retained remains available to interact in subsequent assay procedures.

A solid phase is provided to which has been bound a binding component. In the performance of the assay, which can be simultaneous or sequential, an analyte in solution is mixed with an amount of particle-bound binding component and allowed to react. A second binding component labelled with a signal-generating material, is added and likewise allowed to react, forming an immunocomplex of particle-bound binding component:antigen:labelled second binding component. The complex is then washed to remove unbound labelled binding component and the- reaction area read to measure the amount of signal present, which is correlative with the presence or quantity of analyte present in the specimen.

DESCRIPTION OF THE INVENTION

This invention is directed to a binding component attached to a particulate material used as a solid phase in a heterogeneous immunoassay procedure.

In the course of the invention described herein the following terms will be described and have the following applied meanings: binding component - any molecule, compound, or combination thereof capable of recognizing and binding to a distinct spatial or polar organization of a molecule (commonly referred to as an antigenic determinant or an idiotype); solid phase - material that has been rendered insoluble by binding to the particulate material, as distinguished from the liquid phase which contains soluble material; label - a substance that generates or can be made to generate a signal capable of being detected or measured by visual or instrumentation means; and analyte (of interest) - a compound, substance or organism suspected of being present in a patient sample solution; the presence or absence of which is of interest to the user, and which contains at least one unique spatial or polar organization capable of being recognized and bound by a binding component.

Solid phase im unoassays generally use some type, of solid support surface to which can be bound, directly or indirectly, components which are thereby rendered insoluble with respect to the liquid medium in which the components were dissolved. The principle involved is that by removing the material from the liquid phase, and subsequently washing the solid phase, a more complete separation can occur, which increases the overall sensitivity of the assay. To this end various types and structures of materials have been, chosen for different purposes. Systems use sheets of filter paper, glass, cellulose, or like types of materials, to which the binding component is attached. In some cases the inner or outer surface of a test tube or microtiter tray well is used so as to provide simultaneously a reaction vessel integral with the solid phase. Additionally, beads of various compositions have been used in an effort to increase the surface area of the solid support surface material . The present invention uses a novel relation between finely divided particulate solid material capable of forming a stable suspension in a liquid medium and an inert.porous filter matrix means of sufficient pore size to retain the particles on or within the filter matrix, yet permitting the flow of liquid therethrough. Material thus retained remains available to interact in subsequent assay procedures such as but not limited to washing to separate bound from unbound material, reagent addition, optical measurement, and the like.

The particles can be made of any solid material that meets two requirements. First, it must be suspendable in solution; by this is meant that the particles are insoluble in solution but are small enough to be suspended in the solution. This increases favorable reaction kinetics through Brownian motion, thereby establishing equilibrium faster than a system with less available surface for binding. Second, the material must be filterable: particulate material is capable of being retained on or within a semi-permeable substance, preferably inert with respect to the chemical reactions. Filter material is composed of a substance such as paper, glass fiber, scintered glass, cotton, synthetic polymer, plastic, cellulose, cellulose acetate, polytetrafluoroethylene, polyethylene, polypropylene or polyvinylidine fluoride, and the like. The particles can be made of a wide variety of materials including, but not limited to, glass, cellulose, synthetic polymers or plastics, proteins (e.g., gluteraldehyde or albumin), bacterial cells (e.g., protein A staphylococcus), and the like. Latex is a preferred material because of its availability, cost-effectiveness and ease of use. The size of the particles is limited, again, only by the requirements of suspendability and filterability. The particles should be large enough to be trapped by a given filter material, yet small enough to be suspendable in a liquid medium. They are preferably spheroidal in shape, but the structural and spatial configuration is not critical; for instance, the particles could be slivers, ellipsoids, cubes, and the like. A suitable particle size ranges from a diameter of 0.2um to δO.Oum, preferably between 0.4um to l.Ou .

It is also possible to use as a solid particle organisms which can bind to the antibody directed against them. In such an embodiment the organism would be of a size or diameter that would be suspendable and filterable. An example is Toxoplasma gondii , a parasite of micron dimensions which binds to the antibody specific for it. A labelled anti-antibody directed against the Toxoplasma gondii antibody is used to attach a signal generator to the complex.

While the specific particle size is relevant, the primary focus is on the relationship between the particle size, filter thickness and filter pore size. The filter pore size is defined by the construction of the filter material. In the case of glass fiber filters the size density of the fibers defines the amount and size of the interstices therein. The filter is designed to contain pores or interstices large enough to entrap particles within or on the filter and prevent their passing therethrough. Moreover, the depth or thickness of the filter should be sufficient to permit an effective amount of particles to become entrapped. Were the filter too thin, there should be inadequate space for enough particles to be entrapped to perform a quantitative assay. It is preferable for the particles to be caught within the filter, but some of the particles will remain blocked on its surface, whether because of clumping, aggregation or random nonuniformly sized particles. One advantage of interstice or pore entrapment is the favorable reaction kinetics that result. When the particles are immobilized within the porous filter and fluid must be contacted with the surface of the particles, such as in a wash step, there is greater surface area available for contact if the particles are suspended, as it were, in the filter, with their surfaces virtually completely exposed to the fluid in contact therewith. Where the particles are trapped solely on the surface of a thin membrane incapable of retaining particles in a three dimensional network of pores or interstices, there is less surface area available* because the particles, are in contact with each other, resulting in a decreased surface area; therefore, a less efficient wash or fluid contact occurs, decreasing the efficiency of the assay procedure.

Another advantage of internal, as opposed to external, entrapment is the convenience of physical transport of devices embodying the assay materials. Where particle bound binding component is pre-spotted in the filter, lyophilized, or otherwise immobilized, the filter effectively binds the particles with little possibility of the particles dissociating from the filter during rough handling; Where particles are pre-spotted on top of the surface of a thin membrane, there is a greater likelihood of the particle layer coming off the membrane if dropped, jostled or otherwise disturbed. Additionally, if the particles are deposited as a layer on a membrane, and dried thereon, when reconstituted the layer might float off the membrane and shift its position, potentially reducing the amount of material within a narrowly defined reaction zone. This deficiency is not present in the instant invention because pre-spotted particles are securely immobilized within the filter and not subject to the- same mistreatment. It is inevitable, however, that a certain fraction of the particles will be blocked on the surface of the filter. The method of this invention contemplates the enable ent of the procedure regardless of the amount of surface entrapment that occurs.

The filter itself has the unique characteristic of being able to wick fluid away from the point of application by capillary action while the particles are entrapped in the filter matrix. This permits a Targe volume of fluid to be transported from an area in contact with the particles and other bound components and to an area away therefrom. Since the efficiency of an assay technique is, in part, dependent upon the completeness of separation between bound and unbound material, the greater the volume of wash fluid that is in contact with the components, the more effective the wash. The completeness of the wash reduces the amount of background noise present where unbound signal generating material remains in the zone of measurement. The filter contemplated by the present invention can provide an improved means for accomplishing this desired separation.

The particles have bound to them a binding component, which is rendered insoluble. The binding component is chosen to be able to recognize and bind to an analyte in solution. Typically, where the analyte is an antigen (any substance capable of eliciting an immune response, e.g., group A strep or human chorionic gonadotropin) the binding component is an antibody that will bind to an antigenie WO87/0369° FCT/ SKiαK-7-

-12-

deter inant on the antigen. Where the analyte is an antibody, such as when testing for rubella or hepatitis, the binding component is an antigen. It is also possible for the analyte to be an antibody and the binding component to be an ( ant i ) antibody directed to the analyte antibody. Moreover, it is useful to employ monoclonal antibodies for the particle-bound binding component as well as for the labelled binding component because of the high degree of selectivity and sensitivity associated with such antibodies.

The binding component can be directly attached to the particle material via absorption or covalent chemical bonding, the methods for which are well known in the art. Direct adhering of binding component can be achieved by reacting carbodiimide with the particle and the binding component. Alternatively, serum Protein A is used in a well known procedure. Indirect insolublization of binding component can be achieved by attaching to the particle material a member of a binding pair, such as biotin, and separately attaching to the binding component the other member of the binding pair, such as avidin. When particle-bound biotin is mixed with the binding component -bound avidin the avidin and biotin bond together,. forming a particle-avidin-biotin-binding component linkage. Such a method would be advantageous when it is desirable to insolublize the binding component: analyte complex after it has formed, rather than before. Another technique for indirectly attaching the binding component to the particle material is by binding an antibody to the particle material, separately binding to the binding component a different, ( ant i ) antibody directed against the particle-bound antibody and subsequently mixing the products of each reaction together to form a particle-antibody: (anti)antibody-binding component structure.

Where latex particles and glass fiber filter paper is used, conditioning of the filter is necessary prior to, or contemporaneously with, the addition of insolublized material to the filter means. The " purpose is twofold; first, to enhance the immobilization of latex particles within the interstices; second, to prevent the nonspecific sticking of unbound antibody or other extraneous materials to the filter. The conditioning material can be different for both, such as but not limited to gelatin, horse serum, albumin, dry milk, and the like. The material can.be added to the filter prior to the addition of components to the filter. Alternatively, the conditioning material may be added simultaneously with the other reactants, or, it can even be mixed with the specimen fluid as a diluent or the particle suspension.

The particles coated with binding component are then contacted in a reaction vessel or container with a biological fluid suspected of containing an analyte such as bacterial, viral, fungal or parasitic antigens and im unoglobulins, antibodies, hormones, serum proteins, enzymes, drugs, and the like. Biological fluids from which samples can be obtained include urine, feces, blood, serum, mucus, sputum, semen, and the like. Analyte will form an immunological complex with the insolublized binding component.

Simultaneously, or subsequently, depending on the assay procedure, a second binding component labelled with a signal-generating material is added to the reaction vessel. This labelled binding component commonly is an antibody, directed against the analyte. The antibody has been conjugated with a label prior to its addition to the reaction vessel. Several types of labels are available for use in the present invention, depending upon the type of assay being conducted, including enzyme, luminescent, bioluminescent, chemi-luminescent and radioisotopic materials. The label must be capable of emitting or assist in emitting a signal detectable by visual or instrumentation means. The labelled binding component will bind to the complex thereby providing an indirect means for identifying the presence and quantity of analyte present in the reaction vessel.

The newly formed insoluble immunocomplex of insolublized binding component:analyte:labelled binding component is then washed to remove unbound material which could interfere with the accurate representation - of the label present; namely, label which has nonspecifically bouncl to material in the reaction vessel other than the insolublized immunocomplex, such as proteins, the reaction vessel itself or the particles. The separation is conducted by a filtration procedure involving passing through or into a filter material the reaction mixture, which is retained because of its size in the filter interstices. The immunoche ical reactions can occur within the filter or external thereto. Unbound materials wash through or out of the filter and away from the reaction zone which is to be read. Separation is accomplished by passing fluid through the filter by gravity, capillary action, or by using positive or negative pressure, such as a vacuum or pump means. The completeness of the separation is critical to the sensitivity of the assay; the more unbound material which could emit a detectable signal that is removed the less background noise there will be to interfere or obscure a weak signal being emitted from a very low concentration of bound label.

The wash solution can be a buffer, such as phosphate or TRIS, or any other solution appropriate and compatible with the components involved. Where an enzyme label is used the substrate may be added as part of the wash solution or separately added prior to reading.

The signal is read after any necessary developing, quenching or other modification of the signal. Reading can be done visually or through an instrument, such as a colorimeter to measure color absorbance where an enzyme label is used; a photometer to measure visible light where a luminescent, bioluminescent or chemi-luminescent label is used; or a scintillation or gamma counter to measure radiation where a radioisotope is the label. The amount of signal produced is correlative with the concentration of analyte present in the biological sample fluid; the measurement is useful in diagnosis or monitoring drug levels or disease states.

A preferred embodiment of this invention is a sandwich enzyme immunoassay where the binding component is an antibody and attached to latex particles; the analyte is an antigen; the label is an enzyme; and the substances are added sequentially to a filter material, in which the separation occurs. After washing the insolublized complex a substrate is added to produce a visual indication if antigen is present. The reaction area can also be read by an instrument to provide a sensitive quantitation of the antigen. An advantage of sequential addition is the greater degree of control over the binding reactions that is obtained. For example, where a very low concentration of antigen is suspected of being present, a longer incubation period is required because of the slower reaction kinetics involved; equilibrium will take longer to achieve. The result of the flexibility and control gained is the increased sensitivity for a quantitative measurement of analyte.

Another embodiment of this invention is the simultaneous addition of insolublized binding component, analyte and labelled binding component. An advantage of this embodiment is the elimination of the separate addition steps, thereby saving time for the user. This method is particularly useful where only a qualitative "yes-no" result is desired.

A further embodiment of this invention is a competitive assay whereby sample analyte and labelled analyte compete' for binding sites on the insolublized binding component.

Still another embodiment of this invention is the prespotting of particle-bound binding component in the filter material or separation medium prior to the addition of analyte and other substances. This embodiment has the advantage of allowing for storage of a test device whereby the filter material has been pretreated with a particular particle-bound binding component, enabling a user to perform an assay for a desired analyte and eliminate one step of manipulation, thereby reducing the time and error associated an assay. Furthermore, this embodiment eliminates the step of separately adding the particle bound antibody, thus simplifying the procedure.

An alternative embodiment of this invention utilizes a plurality of monoclonal antibodies insolublized on or within the filter matrix and are designed to recognize and bind different and distinct analytes simultaneously. A plurality of labels of different wavelengths are used to identify the particular analyte and a photometer or other appropriate instrument, used to measure the intensity of the of the signal at the different corresponding wavelengths. In this manner it is possible, in a single test device or reaction area, using a single procedure, to obtain accurate and sensitive determ nations of multiple antigens in a patient sample. A significant example of this is an assay for Gonorrhea and Chlamydia, a test frequently needed in hospitals and physicians' offices. Such a test, using monoclonal antibodies to the Gonorrhea and Chlamydia organisms bound to insolublized particles and a single reaction zone or container, could determine whether either, both or neither of the two organisms was present, employing only a single procedure.

Moreover, using the high selectivity of monoclonal antibodies, this invention could be used to detect the serotype of a particular bacteria, virus, parasite, or other organism where e treatment would be different depending on the particular pathogen present.

Where enzyme labelling is desired a plurality of substrates is use each producing a signal readable by a photometer with monochromatic light. By scanning the spectrum, or using specific wavelengths, the instrument could distinguish the different wavelength signals, which the human eye would normally interpret as one average color.

The Examples which follow further define and illustrate various embodiments of Applicant's invention. They are by way of illustration only and not by way of limitation. Other methods are contemplated as being within the scope and spirit of this invention. EXAMPLES EXAMPLE 1 - PROCEDURE FOR SEQUENTIAL ASSAY

A test to determine the presence of human chorionic gonadotropin (hCG) as an indication of pregnancy is performed on a urine specimen.

First, 5 drops of 0.5% gelatin in Tris buffered saline are added to a glass fiber filter paper (Micro Filtration Systems) to condition the filter. Then 4 ml of 2.5% latex particles (average diameter of 1 urn, Polysciences) are added to 1 mg/ml solution of a monoclonal antibody directed against hCG and mixed for three hours, then centrifuged. One drop of the urine specimen is added to 1 drop of the antibod -coated latex particles and the mixture permitted to incubate for one minute. One drop' of β second monoclonal antibody directed against a different and distinct epitope on the hCG molecule and labelled with alkaline phosphatase is then added and the mixture is added to the filter and the filtrate washed with 1 ml Tris buffer solution. One drop of indoxyl phosphate substrate is added to the washed mixture to develop color. Appearance of a blue color is indicative of a positive result.

EXAMPLE 2 - PROCEDURE FOR SIMULTANEOUS SANDWICH ASSAY

The procedure according to EXAMPLE 1 is used; but, the antibody coated latex particles, urine specimen and labelled second antibody are mixed simultaneously and then incubated. Again, appearance of a blue color indicates a positive result. EXAMPLE 3 - PROCEDURE FOR SIMULTANEOUS COMPETITIVE ASSAY

A test to determine the presence and/or quantisation of digoxin.

First, 5 drops of 0.5% gelatin in Tris buffered saline solution are added to a glass fiber filter paper (Micro Filtration Systems) to condition the filter. Then 4 ml of 2.5% latex particles (1 urn average diameter, Polysciences) are added to 1 mg/ml solution of a monoclonal antibody directed against digoxin and mixed for 3 hours, then centrifuged. One to 10 drops of a serum specimen suspected of containing digoxin and 1 drop of alkaline phosphatase labelled digoxin are combined with an excess amount of latex coated with monoclonal antibody and incubated for 1 hour. The mixture is added to the filter and washed with 1 ml of Tris buffered saline to remove unbound digoxin. Then 1 drop of indoxyl phosphate substrate is added to the washed * mixture. The appearance of a blue color is indicative of the presence of digoxin.

EXAMPLE 4 - PROCEDURE FOR SEQUENTIAL COMPETITIVE ASSAY

A test to determine the presence of thyroid stimulating hormone (TSH).

First, 5 drops of 0.5% gelatin in Tris buffered saline are added to a glass fiber filter paper (Micro Filtration Systems) to condition the filter. Then, 4 ml of 2.5% latex particles (average diameter of 1 urn, Polysciences) are added to 1 mg/ml solution of a monoclonal antibody directed against TSH and mixed for 3 hours, then centrifuged.

One to 10 drops of alkaline phosphatase conjugated TSH are added to 1 drop of the latex bound monoclonal antibody and incubated. The mixture is added to the conditioned filter and washed with 1 ml of Tris buffered saline to remove unbound material. One drop of blood serum specimen suspected of containing TSH is added to the filter and allowed to react. The mixture is again washed with Tris buffered saline to remove unbound material. Then, 1 drop of indoxyl phosphate is added. The appearance of a blue color is indicative of the presence of TSH. A quantitative measurement of TSH can be made by reading the reaction zone with a colorimeter or similar instrument.

While the invention has been described in connection with a preferred embodiment, it is not intended to limit the scope of the invention to the particular form set forth, but, on the contrary, it is intended to cover such alternatives, modifications, and equivalents as may be included within the spirit and scope of the invention as defined by the appended claims.

Claims

WHAT IS CLAIMED IS:
1. An immunoassay method for the detection or quantitation of an analyte suspected of being in a specimen solution comprising:
(a) passing said specimen, insoluble particles, a first binding component capable of being bound to said particles, and second binding component labelled with a signal generating material to a filter means having a sufficient pore size such that said particles are trapped within said filter yet permitting rapid passage of fluid therethrough in such a manner that an immunological reaction occurs if analyte is present in said specimen, resulting in the formation of an immunocomplex of insolublized first binding component:analyte:second labelled binding component on or within said filter means;
(b) separating bound from unbound material; and
(c) determining the presence and/or amount of signal produced which is correlative with the amount of analyte present in the solution.
2. The method of claim 1 wherein said first binding component is bound to said particles prior to mixing with other reactants or addition to said filter means.
3. The method of claim 2 wherein said first binding component is covalently bound to said particles by chemical reaction in an amount sufficient to substantially coat said particles.
4. The method of claim 3 wherein said first binding 'component is bound to said particles by specific biological binding so as to substantially coat said particles.
5. The method of claim 4 wherein said first binding component is " first bound to avidin, said particles are bound to biotin such that when mixed together a first binding component-avidin-biotin-particle structure forms effectively coating said particles.
6. The method of claim 2 comprising the further steps of:
(a) immobilizing said first binding component coated particles in said filter means; then
(b) contacting with said immobilized first binding component coated particles a specimen solution suspected of containing an analyte of interest such that a complex forms between said first
-binding component and any of said analyte present; and then
(c) .contacting with said complex said second labelled binding component that will preferentially bind to said complex within said filter means.
7. The method of claim 2 comprising the further steps of:
(a) contacting with said first binding component coated particles a specimen suspected of containing an analyte of interest such that a complex forms with any of said analyte present; then
(b) adding any of said complex formed to said filter means; and then
(c) contacting with said complex said second labeled binding component that will preferentially bind to said complex within said filter means.
8. The method of claim 2 comprising the further steps of: (a) mixing said first binding component coated particles, specimen suspected of containing an analyte of interest and said second labelled binding component such that a complex forms; and then
(b) adding any of said complex formed to said filter means.
9. The method of claim 2 wherein said first binding component, specimen and second labelled binding component are mixed together simultaneously.
10. The method of claim 1 wherein said analyte is an antigen capable of being recognized by an antibody of interest suspected of being in a specimen.
11. The method of claim 10 wherein said analyte is selected from rubella virus, HTLV, cytomegalovi rus or. herpes virus.
12. The method of claim 1 wherein said label is selected from an enzyme, radioactive, ferromagnetic, luminescent, bioluminescent or chemi luminescent material.
13. The method of claim 1 wherein said label is an enzyme.
14. The method of claim 13 wherein said enzyme is alkaline phosphatase.
15. The method of claim 14 comprising the further step of: adding a substrate specific for said enzyme subsequent to said washing of said complex so as to produce a colored product if analyte is present in said specimen.
16. The method of claim 1 wherein said first binding component is a polyclonal antibody.
17. The method of claim 1 wherein said first binding component is a monoclonal antibody.
18. The method of claim 1 wherein said second binding component is a polyclonal antibody.
19. The method of claim 1 wherein said second binding component is a monoclonal antibody.
20. The method of claim 1 wherein both binding components are monoclonal antibodies.
21. The method of claim 20 wherein both monoclonal antibodies are a product of the same cell line.
22. The method of claim 20 wherein both monoclonal antibodies are products of different cell lines.
23. The method of claim 1 wherein subsequent to the addition of second labelled binding component any of the complex thereformed is added to a filter means capable of effecting a separation of bound from unbound material ..
24. The method of claim 1 wherein said separation of bound from unbound material is accomplished by the addition to said immobilized complex of a wash fluid capable of passing through said filter means either transversely or vertically carrying with it said unbound material .
25. The method of claim 1 wherein said filter means is a solid phase retention and separation apparatus comprising a substantially inert porous flat filter matrix of sufficient uniform pore size to retain said insolublized complex on or within its pores yet permitting the flow of liquid therethrough.
26. The method of claim 25 wherein said filter means is capable of effecting a filter separation of an insolublized component from a solublized component when a liquid is applied to said filter means and. wicked through its pores by capillary action.
27. The method of claim 26 wherein said filter means is composed of a material selected from glass fiber filter paper, nitrocellulose, plastic, synthetic polymer, cellulose, cellulose acetate, polytetrafluoroethylene, polyethylene, polypropylene or polyvinylidine fluoride.
28. The method of claim 27 wherein said filter means is composed of glass fiber filter paper.
29. The method of claim 27 wherein said filter means comprises a micro-porous membrane having substantially uniform pores between 25 nanometers and 25 micrometers, said pores defining integral surfaces in said membrane.
30. The method of claim 1 wherein said particles are composed of a material of sufficient size to be suspendable in a solution and entrapable on the surface or within the pores or interstices of said filter means when in contact therewith.
31. The method of claim 30 wherein said particle material is composed of a material selected from the group consisting of latex, glass, cellulose, synthetic polymers or plastics, proteins or bacterial cells.
32. The method of claim 31 wherein said particles have a size between 0.2um and 50um, preferably between 0.4um and lum.
33. The method of claim 31 wherein said particle material is composed of latex.
34. The method of claim 1 wherein said analyte is a substance capable of eliciting an immune response selected from the group consisting of an antigen, antibody, bacteria, drug, fungus, hapten, hormone, parasite, protein, tumor cell marker or virus. -
35. The method of claim 1 wherein said analyte is a plurality of distinct antigens capable of detection or quantisation, said particle bound binding component is a plurality of monoclonal antibodies each being directed against a particular antigen, said labelled second binding component is a plurality of monoclonal antibodies directed against a particular and distinct antigen whereby each of said second labelled monoclonal antibodies are labelled with a different label each capable of emitting a distinctly recognizable signal.
36. The method of claim 35 wherein each of said plurality of labels is detected or quantified by monochromatic light at the appropriate wavelength as part of a photometric measurement.
37. The method of claim 35 wherein said analytes are Neisseria gonorrhea and Chlamydia.
38. The method of claim 37 wherein one of said particle bound monoclonal antibodies is substantially exclusively directed against Neisseria gonorrhea and the other said particle bound monoclonal antibody is substantially exclusively directed against Chlamydia.
39. The method of claim 38 wherein one said labelled second monoclonal antibody is directed said Neisseria gonorrhea and another labelled second monoclonal antibody is directed against said Chlamydia wherein each label emits a different and distinct signal.
40. An immunoassay method for the detection or quantitation of human chorionic gonadotropin (hCG) suspected of being in a specimen comprising:
(a) contacting a first monoclonal antibody directed against hCG and bound to finely divided particulate latex capable of forming a stable suspension in a liquid medium with a delimited area defining a reaction zone on or within a solid phase retention and separation system said system being a glass fiber filter paper means of sufficient pore size to retain said latex bound material on or within the pore of said filter means yet permitting the flow of fluid therethrough;
(b) adding to said reaction zone on or within said filter means said specimen in a manner favoring the formation of a complex of first monoclonal antibody and any hCG present;
(c) adding to said reaction zone an alkaline phosphatase labelled second monoclonal antibody which is directed against a different and distinct idiotypic determinant on said hCG in a manner favoring the formation of a complex;
(d) incubating said reaction zone for a sufficient time to effect the immunobinding of first monoclonal antibody, alkaline phosphatase labelled second monoclonal antibody and hCG;
(e) washing said reaction zone with a solution of Tris buffered saline in an amount sufficient to effect a separation of bound from unbound material;
(f) adding an effective amount of 3-indolyl phosphate to said reaction zone to develop a colored product if any of said complex is present; (g) reading said reaction zone to determine the presence or amount of colored product as correlative with the presence and/or concentration of hCG present in said specimen.
41. The method of claim 40 further comprising contacting with said filter means an effective amount of a solution of conditioning material in a manner that promotes the entrapment of particles on or within said filter means so as to prevent the nonspecific binding of undesirable substances to said filter means.
42. The method of claim 41 wherein said conditioning material is a protein or synthetic polymer solution.
43. The method of claim 42 wherein said conditioning material is a mixture of two different substances in solution.
44. The method of claim 43 wherein said conditioning material is selected from gelatin, horse serum, albumin dry milk or dextran.
45. The method of claim 42 or 43 wherein said conditioning material is added to said filter means prior to or simultaneously with the addition of said particles to said filter means.
PCT/US1986/002637 1985-12-10 1986-12-10 Particle-bound binding component immunoassay WO1987003690A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US80715785 true 1985-12-10 1985-12-10
US807,157 1985-12-10

Publications (1)

Publication Number Publication Date
WO1987003690A1 true true WO1987003690A1 (en) 1987-06-18

Family

ID=25195717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/002637 WO1987003690A1 (en) 1985-12-10 1986-12-10 Particle-bound binding component immunoassay

Country Status (2)

Country Link
EP (1) EP0248892A1 (en)
WO (1) WO1987003690A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2599845A1 (en) * 1986-06-09 1987-12-11 Liotta Lance A Device for the determination of the presence of antigens in a sample and method for its implementation
US4870007A (en) * 1987-12-18 1989-09-26 Eastman Kodak Company Immobilized biotinylated receptor in test device, kit and method for determining a ligand
EP0341439A1 (en) * 1988-05-11 1989-11-15 Abbott Laboratories Method for increasing specificity in competitive immunoassays
EP0363091A2 (en) * 1988-10-07 1990-04-11 Johnson & Johnson Clinical Diagnostics, Inc. Immunological reagent composition and its use in the determination of chlamydial or gonococcal antigens
WO1990009593A1 (en) * 1989-02-09 1990-08-23 Eastman Kodak Company Method and kit for determination of herpes simplex viral antigen by direct binding to polymeric particles
US4965191A (en) * 1988-02-12 1990-10-23 Eastman Kodak Company Lower alcohol sulfate wash solution, test kit and method for the determination of an immunological ligand
EP0411944A2 (en) * 1989-08-04 1991-02-06 BEHRINGWERKE Aktiengesellschaft Heterogeneous binding assays
US5017474A (en) * 1988-02-12 1991-05-21 Eastman Kodak Company Wash solution, test kit and method for the determination of an immunological ligand
EP0456308A1 (en) * 1990-05-11 1991-11-13 Clinical Diagnostic Systems, Inc. Immunoreagent composition, test kit and rapid assay for human chorionic gonadotropin
FR2664704A1 (en) * 1990-07-11 1992-01-17 Bio Merieux Process for the detection of a biological substance in a liquid medium according to a filtration technique which makes it possible to retain the biological substance upon the particles not passing through the filter
US5094962A (en) * 1988-06-13 1992-03-10 Eastman Kodak Company Microporous article having a stabilized specific binding reagent, a method for its use and a diagnostic test kit
EP0488755A1 (en) * 1990-11-29 1992-06-03 Wako Pure Chemical Industries, Ltd Process for rapid measurement of trace components
US5185128A (en) * 1988-02-12 1993-02-09 Eastman Kodak Company Test kit containing labeled receptor and wash solution for determination of an immunological ligand
WO1994028420A1 (en) * 1993-05-22 1994-12-08 Rhone Poulenc Diagnostics Ltd Method of detection of bacteria
EP0802411A2 (en) * 1996-03-14 1997-10-22 Tosoh Corporation Measurement method and kit for hemoglobin A1c
WO1998002743A1 (en) * 1996-07-15 1998-01-22 Sensors Technology Company B.V. Sensors
WO2001031337A2 (en) * 1999-10-27 2001-05-03 Genosis Limited Lateral flow device utilising particulate carrier
WO2002062941A1 (en) * 2001-02-05 2002-08-15 Micap Plc Detection of micro-organisms
US7547384B2 (en) 2002-04-04 2009-06-16 Millipore Corporation Electrochemical detector systems

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966897A (en) * 1973-04-02 1976-06-29 Marine Colloids, Inc. Medium for use in bioassay and method of using same
US4185084A (en) * 1976-10-07 1980-01-22 Mochida Seiyaku Kabushiki Kaisha Immunochemical measuring method using second antigenic substance
US4197361A (en) * 1977-08-23 1980-04-08 Warner-Lambert Fluorescent immunoassay sandwich technique for HBs Ag
US4200436A (en) * 1976-09-30 1980-04-29 Mochida Seiyaku Kabushiki Kaisha Immunochemical measuring process
US4248965A (en) * 1976-10-07 1981-02-03 Mochida Seiyaku Kabushiki Kaisha Immunochemical process of measuring physiologically active substances
US4446232A (en) * 1981-10-13 1984-05-01 Liotta Lance A Enzyme immunoassay with two-zoned device having bound antigens
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4582792A (en) * 1982-05-10 1986-04-15 Fujirebio Kabushiki Kaisha Immunoassay method using two immobilized biologically active substances

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966897A (en) * 1973-04-02 1976-06-29 Marine Colloids, Inc. Medium for use in bioassay and method of using same
US4200436A (en) * 1976-09-30 1980-04-29 Mochida Seiyaku Kabushiki Kaisha Immunochemical measuring process
US4185084A (en) * 1976-10-07 1980-01-22 Mochida Seiyaku Kabushiki Kaisha Immunochemical measuring method using second antigenic substance
US4248965A (en) * 1976-10-07 1981-02-03 Mochida Seiyaku Kabushiki Kaisha Immunochemical process of measuring physiologically active substances
US4197361A (en) * 1977-08-23 1980-04-08 Warner-Lambert Fluorescent immunoassay sandwich technique for HBs Ag
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4446232A (en) * 1981-10-13 1984-05-01 Liotta Lance A Enzyme immunoassay with two-zoned device having bound antigens
US4582792A (en) * 1982-05-10 1986-04-15 Fujirebio Kabushiki Kaisha Immunoassay method using two immobilized biologically active substances

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2599845A1 (en) * 1986-06-09 1987-12-11 Liotta Lance A Device for the determination of the presence of antigens in a sample and method for its implementation
BE1001736A4 (en) * 1986-06-09 1990-02-20 Liotta Lance A Multilayer immunoassay wherein antibodies are used which are bound to transport particles, for determining the presence of an antigen.
US4870007A (en) * 1987-12-18 1989-09-26 Eastman Kodak Company Immobilized biotinylated receptor in test device, kit and method for determining a ligand
US5185128A (en) * 1988-02-12 1993-02-09 Eastman Kodak Company Test kit containing labeled receptor and wash solution for determination of an immunological ligand
US5599715A (en) * 1988-02-12 1997-02-04 Johnson & Johnson Clinical Diagnostics, Inc. Lower alcohol sulfate wash solution
US5017474A (en) * 1988-02-12 1991-05-21 Eastman Kodak Company Wash solution, test kit and method for the determination of an immunological ligand
US4965191A (en) * 1988-02-12 1990-10-23 Eastman Kodak Company Lower alcohol sulfate wash solution, test kit and method for the determination of an immunological ligand
EP0341439A1 (en) * 1988-05-11 1989-11-15 Abbott Laboratories Method for increasing specificity in competitive immunoassays
US6150113A (en) * 1988-05-11 2000-11-21 Abbott Laboratories Method for increasing specificity in competitive immunoassays
US5094962A (en) * 1988-06-13 1992-03-10 Eastman Kodak Company Microporous article having a stabilized specific binding reagent, a method for its use and a diagnostic test kit
EP0363091A2 (en) * 1988-10-07 1990-04-11 Johnson & Johnson Clinical Diagnostics, Inc. Immunological reagent composition and its use in the determination of chlamydial or gonococcal antigens
EP0363091A3 (en) * 1988-10-07 1990-09-12 Eastman Kodak Company Immunological reagent composition and its use in the determination of chlamydial or gonococcal antigens
WO1990009593A1 (en) * 1989-02-09 1990-08-23 Eastman Kodak Company Method and kit for determination of herpes simplex viral antigen by direct binding to polymeric particles
US5155021A (en) * 1989-02-09 1992-10-13 Eastman Kodak Company Method and kit for determination of herpes simplex viral antigen by direct binding to polymeric particles
EP0411944A2 (en) * 1989-08-04 1991-02-06 BEHRINGWERKE Aktiengesellschaft Heterogeneous binding assays
US5437983A (en) * 1989-08-04 1995-08-01 Syntex (U.S.A.) Inc. Heterogeneous binding assays
EP0411944A3 (en) * 1989-08-04 1991-10-30 Syntex (U.S.A.) Inc. Heterogeneous binding assays
EP0456308A1 (en) * 1990-05-11 1991-11-13 Clinical Diagnostic Systems, Inc. Immunoreagent composition, test kit and rapid assay for human chorionic gonadotropin
FR2664704A1 (en) * 1990-07-11 1992-01-17 Bio Merieux Process for the detection of a biological substance in a liquid medium according to a filtration technique which makes it possible to retain the biological substance upon the particles not passing through the filter
US5677194A (en) * 1990-11-29 1997-10-14 Wako Pure Chemical Industries, Ltd. Process for rapid measurement of trace components
EP0488755A1 (en) * 1990-11-29 1992-06-03 Wako Pure Chemical Industries, Ltd Process for rapid measurement of trace components
WO1994028420A1 (en) * 1993-05-22 1994-12-08 Rhone Poulenc Diagnostics Ltd Method of detection of bacteria
EP0802411A2 (en) * 1996-03-14 1997-10-22 Tosoh Corporation Measurement method and kit for hemoglobin A1c
EP0802411A3 (en) * 1996-03-14 1998-09-09 Tosoh Corporation Measurement method and kit for hemoglobin A1c
WO1998002743A1 (en) * 1996-07-15 1998-01-22 Sensors Technology Company B.V. Sensors
WO2001031337A2 (en) * 1999-10-27 2001-05-03 Genosis Limited Lateral flow device utilising particulate carrier
WO2001031337A3 (en) * 1999-10-27 2001-09-20 Genosis Ltd Lateral flow device utilising particulate carrier
WO2002062941A1 (en) * 2001-02-05 2002-08-15 Micap Plc Detection of micro-organisms
US8956880B2 (en) 2001-02-05 2015-02-17 Micap Plc Detection of micro-organisms
US7547384B2 (en) 2002-04-04 2009-06-16 Millipore Corporation Electrochemical detector systems

Also Published As

Publication number Publication date Type
EP0248892A1 (en) 1987-12-16 application

Similar Documents

Publication Publication Date Title
US4870005A (en) Multilayer analysis element
US5939331A (en) Red blood cell separation means for specific binding assays
US4197088A (en) Method for qualitative and quantitative determination of immunological reactions
US5006464A (en) Directed flow diagnostic device and method
US4727019A (en) Method and apparatus for immunoassays
US5714389A (en) Test device and method for colored particle immunoassay
US4870007A (en) Immobilized biotinylated receptor in test device, kit and method for determining a ligand
US5565366A (en) Kits and ligand assay plates using two-tiered separation for detection of immunoreagent particles
US4400353A (en) Electro-optical system for use in evaluating immunological reactions
US5616467A (en) Method and kit for analyte detection employing gold-sol bound antibodies
US4859612A (en) Metal sol capture immunoassay procedure, kit for use therewith and captured metal containing composite
US20030119204A1 (en) Internal calibration system for flow-through assays
US5270166A (en) Immunoassays employing generic anti-hapten antibodies and materials for use therein
US5374531A (en) Immunoassay for determination of cells
US5405784A (en) Agglutination method for the determination of multiple ligands
US4786589A (en) Immunoassay utilizing formazan-prelabeled reactants
US4912034A (en) Immunoassay test device and method
US4789628A (en) Devices for carrying out ligand/anti-ligand assays, methods of using such devices and diagnostic reagents and kits incorporating such devices
US5759866A (en) Device and method for assaying biological components in sample
US5006474A (en) Bi-directional lateral chromatographic test device
EP0421294A2 (en) Improved self-performing immunochromatographic device
US20070224701A1 (en) Combination vertical and lateral flow immunoassay device
US5149622A (en) Solid phase analytical device and method for using same
US20040043512A1 (en) Self-calibration system for a magnetic binding assay
US4430436A (en) Analytical element and method of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR FI JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWW Wipo information: withdrawn in national office

Ref document number: 1987900493

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987900493

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1987900493

Country of ref document: EP